Atorvastatin only comes in the form of a tablet you take by mouth.
/viewarticle/937371
Blood pressure response is dose-related over the range of 20 to 80 mg [see Clinical Studies (14.1)]. encoded search term (telmisartan (Micardis)) and telmisartan (Micardis) Lack of Psychiatric Drug Research Creates Clinical 'Crisis'Telmisartan, Valsartan Lower Risk of CVD Complications in DiabeticsVitamin D and Risk of All-cause and Cause-specific MortalityWhite Coat Hypertension May Progress to Hypertension in KidsMany Providers Don't Follow Hypertension GuidelinesShare cases and questions with Physicians on Medscape consult.
On eHealthMe, you can check real-world data from 16 million patients, and personalize the results to your gender and age.
2001 These are not all the possible side effects of Micardis. The usual starting dose of MICARDIS tablets is 40 mg once a day.
Your list will be saved and can be edited at any time.The above information is provided for general 2001 Atorvastatin oral tablet is available as both a generic drug and a brand-name drug.Brand name: Lipitor.
2002 https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvbWljYXJkaXMtdGVsbWlzYXJ0YW4tMzQyMzIy This website also contains material copyrighted by 3rd parties. Please confirm that you would like to log out of Medscape.
The study is created by eHealthMe based on reports of 1,820 people who take Lipitor and Micardis from the FDA, and is updated regularly. Remember that statin medications can reduce your risk of a heart attack or stroke, and the risk of life-threatening side effects from statins is very low.
Maintenance dose: 40 to 80 mg orally once a day. If you log out, you will be required to enter your username and password the next time you visit.
and formulary information changes.
40 mg/day PO initially; titrated to 20-80 mg/day PO, depending on response; patients with volume depletion should receive the lower dosage initially, under close supervisionMost of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeksWhen additional blood pressure reduction is required after the 80-mg dose, a diuretic may be addedIndicated for cardiovascular (CV) risk reduction in patients unable to take ACE inhibitorsUnknown whether doses lower than 80 mg are effective in reducing the risk of cardiovascular morbidity and mortalityRenal impairment: No dosage adjustment necessary; hemodialysis (HD) patients at risk for orthostatic hypotensionUse of telmisartan with an ACE inhibitor is not recommendedAutonomic nervous system: Impotence, increased sweating, flushingCardiovascular: Palpitations, dependent edema, angina pectoris, tachycardia, leg edema, abnormal ECGCentral nervous system: Insomnia, somnolence, migraine, vertigo, paresthesia, involuntary muscle contractions, hypoesthesiaGastrointestinal: Flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, nonspecific gastrointestinal disordersMetabolic: Gout, hypercholesterolemia, diabetes mellitusResistance mechanism: Infection, fungal infection, abscess, otitis mediaRespiratory: Asthma, bronchitis, rhinitis, dyspnea, epistaxisSkin: Dermatitis, rash, eczema, pruritus; Urinary: micturition frequency, cystitis; Special senses: Abnormal vision, conjunctivitis, tinnitus, earacheMost frequent spontaneously reported events include: headache, dizziness, asthenia, coughing, nausea, fatigue, weakness, edema, face edema, lower limb edema, angioneurotic edema, urticaria, hypersensitivity, sweating increased, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, blood pressure increased, hypertension aggravated, hypotension (including postural hypotension), hyperkalemia, syncope, dyspepsia, diarrhea, pain, urinary tract infection, erectile dysfunction, back pain, abdominal pain, muscle cramps (including leg cramps), myalgia, bradycardia, eosinophilia, thrombocytopenia, uric acid increased, abnormal hepatic function/liver disorder, renal impairment including acute renal failure, anemia, increased CPK, anaphylactic reaction, tendon pain (including tendonitis, tenosynovitis), drug eruption (toxic skin eruption mostly reported as toxicoderma, rash, and urticaria), hypoglycemia (in diabetic patients), and angioedema (with fatal outcome)Hypersensitivity to telmisartan or any other component of this product Coadministration with aliskiren in patients with diabetesUse of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and deathHyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levelAs the majority of telmisartan is eliminated by biliary excretion, patients with biliary obstructive disorders or hepatic insufficiency can be expected to have reduce clearancePregnancy (2nd and 3rd trimesters); significant risk of fetal or neonatal morbidity and mortality (see Black Box Warnings)Dual blockade of the renin-angiotensin system with angiotensin-receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, or aliskiren is associated with increased risk of hypotension, hyperkalemia, and altered renal function (including acute renal failure) in comparison with monotherapyMost patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy; avoid combined use of RAS inhibitors; closely monitor blood pressure, renal function and electrolytes in patients on benazepril and other agents that affect the RASMay cause fetal harm when administered to a pregnant womanUse of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and deathMost epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agentsWhen pregnancy is detected, discontinue as soon as possibleThere is no information regarding the presence of telmisartan in human milk, the effects on the breastfed infant, or the effects on milk productionAdvise a nursing woman not to breastfeed during treatmentA: Generally acceptable.